Abstract
The positive roles of the Wnt/β-catenin pathway in osteoblast differentiation and bone mineral density (BMD) maintenance have been clearly demonstrated in both animal experiments and clinical investigations. CXXC finger protein 5 (CXXC5), a recently identified negative regulator of the Wnt/β-catenin pathway, showed altered cellular localization and function, which were dependent on the cell type in previous studies. However, the in vivo function of CXXC5 has not been clearly investigated yet. Here, we characterized CXXC5 as a negative regulator of osteoblast differentiation and bone formation. Deficiency of CXXC5 resulted in elevated BMD in mice without any severe gross developmental abnormalities. CXXC5 exerted a negative-feedback effect on the Wnt/β-catenin pathway via Wnt-dependent binding to Dishevelled (Dvl) during osteoblast differentiation. Suppression of the Dvl–CXXC5 interaction using a competitor peptide resulted in the activation of the Wnt/β-catenin pathway and osteoblast differentiation, and accelerated thickness growth of ex vivo-cultured calvariae. Overall, CXXC5 is a negative-feedback regulator induced by Wnt/β-catenin signaling that inhibits osteoblast differentiation and bone formation via interaction with Dvl.
Bone is an extremely dynamic tissue at the microscopic level. A dynamic process, called bone remodeling, takes place seamlessly in the bone to repair microdamage and to replace old bone with new bone.1 The resorption of old bone and the formation of new bone must be in balance to maintain homeostasis and a constant mass of bone. Osteoblasts have been identified as an essential factor in regulation of the bone remodeling process, which produce bone matrix and differentiate into osteocytes for bone formation, as well as regulate differentiation and activation of osteoclasts for bone resorption.2
The Wnt/β-catenin pathway is receiving increased attention as a main regulatory pathway for osteoblast differentiation.2, 3, 4 Wnt-dependent nuclear accumulation of an effector protein of the pathway, β-catenin, is a major trigger of osteoblast differentiation and bone formation.2 Many other intracellular and extracellular components of the Wnt/β-catenin pathway are known to regulate osteoblast differentiation.4 Especially two negative regulators of this pathway, Dickkopf 1 and sclerostin, have been highlighted as osteoblast and osteocyte-specific negative regulators of bone formation.5
CXXC finger protein 5 (CXXC5) is a member of a small protein family in which the members contain CXXC-type zinc-finger domain.6 However, unlike other members of this family, CXXC5 lacks a KFGG motif, which is essential for non-methylated CpG recognition that regulates chromatin remodeling.7 CXXC5 localizes to the cytosol or nucleus depending on particular cell type in different tissues. Localization of CXXC5 in the nucleus was observed in promyelocytic leukemia cells.7 CXXC5 has a role as a nuclear transcription activator for Flk-1 and stimulates the embryonic endothelial differentiation in murine embryonic stem cells (mESCs).8 Meanwhile, CXXC5 localized at the cytosol of neural stem cells and interacts with Dishevelled (Dvl) to inhibit the Wnt/β-catenin pathway9 similar to another CXXC-type zinc-finger protein lacking the KFGG motif, Idax (CXXC4).10 However, most experiments were performed using in vitro cell culture systems, and no clear evidence for the in vivo function of CXXC5 has been suggested yet. In this study, we found that CXXC5 localizes to the cytosol of pre-osteoblasts. CXXC5 functions as a negative-feedback regulator of the Wnt/β-catenin pathway inhibiting osteoblast differentiation via Wnt3a-dependent binding to Dvl. CXXC5 knockout resulted in increased bone mineral density (BMD) and trabecular number in mice, which reveals a possible role for the Dvl–CXXC5 interaction in the regulation of bone formation. The role of this interaction was confirmed by experiments using a competitor peptide of the Dvl–CXXC5 interaction, which induced osteoblast differentiation and enhanced bone formation in ex vivo-cultured calvariae. Overall, we suggest that CXXC5 is a negative-feedback regulator of bone formation, and that the Dvl–CXXC5 interaction is an essential regulatory mechanism of bone formation via the Wnt/β-catenin pathway.
Results
CXXC5 −/− mice show high bone mass phenotypes
CXXC5 is evolutionary conserved among vertebrates from zebrafish to humans (Supplementary Figure S1A). In adult mice, CXXC5 mRNA and protein were expressed in several tissues, including muscle, pancreas, colon, skin and bone (Supplementary Figures S1B and C). To identify the in vivo role of CXXC5, we generated CXXC5−/− mice by homologous recombination, replacing exon 2 (which contains the ATG start codon) with the phosphoglycerate kinase gene promoter and the neomycin resistance gene (PGK-Neo; Figure 1a). Disruption of the CXXC5 gene in mESCs was confirmed by Southern blot analysis (Supplementary Figure S2A), and the CXXC5 deletion was confirmed in mice by PCR analysis of tail genomic DNA (Supplementary Figure S2B). CXXC5 knockout was also confirmed by immunohistochemical analysis of adult mouse tissues including kidney tissue; the level of CXXC4, the CXXC5 analog known as Idax,10 was not altered in CXXC5−/− mice (Supplementary Figure S2C).
CXXC5−/− mice were born at the expected Mendelian ratios and no severe gross developmental abnormalities were observed in these mice. Interestingly, the skeleton of 11-week-old CXXC5−/− mice, which were visualized by Alizarin red S staining, showed enlargements of the skull, scapula, spine, ribs and limb bones compared with wild-type mice (Figure 1b). For quantitative analysis, BMDs of the 11-week-old mice were measured using dual-energy X-ray absorptiometry (Figures 1c–e). Average whole-body BMDs increased by 8.9% in CXXC5−/− mice compared with wild-type and CXXC5+/− mice (Figure 1d). Average femoral BMDs increased by 20.0% in CXXC5−/− mice compared with wild-type mice (Figure 1e).
Three-dimensional (3D) micro-computed tomography (CT) demonstrated that tibiae, fibulae, metatarsals and digits of 11-week-old CXXC5−/− mice were larger than those of wild-type mice (Figure 2a). Horizontal sections of the midpoints of the tibia and fibula, visualized by micro-CT scanning, revealed significantly increased cortical bone thickness of tibiae and fibulae in the CXXC5−/− mice (Figures 2b and c). These analyses also revealed the tendency of the femoral bone volume density to increase and a significant increase in the BMD of CXXC5−/− mice compared with wild-type littermates (Figures 2d–f). The number of femoral trabecular bone also showed a tendency to increase, whereas separations between trabecular bones decreased significantly in CXXC5−/− mice (Figures 2d, g and h).
CXXC5 −/− mice show increased osteocyte dendrite formation and bone formation rate
To further investigate the bone phenotype of CXXC5−/− mice, the tibiae of wild-type and CXXC5−/− mice were subjected to histological analyses. The increments of length and thickness of tibiae in CXXC5−/− mice were revealed by the hematoxylin and eosin (H&E) staining of longitudinal sections of the tibiae (Figures 3a and b). Dentin matrix acidic phosphoprotein-1 (DMP-1) is an important osteocyte marker that regulates the biomineralization activity and dendritic outgrowth of osteocytes.11 The numbers of β-catenin- and DMP-1-positive cells were higher in femoral sections from CXXC5−/− mice than those from wild-type mice (Figure 3c). Furthermore, DMP-1 expression levels were higher in the osteocytes of CXXC5−/− mice (Supplementary Figure S3A, and Figures 3c and d). The number and length of osteocyte dendrites, which are essential for osteocytes to function as regulators of bone turnover and mechanosensors,12 were also higher in CXXC5−/− mice than in wild-type mice (Figures 3d–f, and Supplementary Figure S3B). Calcein double-labeling analyses13 showed that bone formation by osteoblasts was accelerated in the femur of CXXC5−/− mice (Figures 3g and h, and Supplementary Figures S3A and B). These results show that CXXC5 deficiency resulted in the enhancement of osteocyte functions, which could be the consequential results of the activation of osteoblasts differentiation.
CXXC5 acts as a negative-feedback regulator of the Wnt/β-catenin pathway and osteoblast differentiation via its transcriptional induction and subsequent enhancement of Dvl interactions in a Wnt3a-dependent manner
The function of CXXC5 in osteoblast differentiation was investigated using MC3T3E1 cells (a murine pre-osteoblast cell line).14 Interestingly, during cellular differentiation, the expression kinetics of both the CXXC5 mRNA and protein levels were similar to those of alkaline phosphatase (ALP), an osteoblast marker,14 and bone sialoprotein (BSP), a common osteoblast differentiation marker gene,14 especially at the late stages of differentiation (>14 days; Figure 4a). The activation of the Wnt/β-catenin pathway during the differentiation of MC3T3E1 cells into osteoblasts was confirmed by the induction of fibroblast growth factor 18 (Fgf18), a direct and specific target of the Wnt/β-catenin pathway,15 and by an increase in the level of β-catenin (Figures 4a and b). CXXC5 was confirmed as a Wnt/β-catenin signaling-inducible gene based on the increase in CXXC5 mRNA in response to β-catenin overexpression (Supplementary Figure S4A). The induced CXXC5 was localized to the cytosol (Figure 4b). Immunoprecipitation (IP) experiments revealed that endogenous CXXC5 interacted with Dvl in MC3T3E1 cells (Supplementary Figure S4B). The interaction between CXXC5 and Dvl was increased in differentiated MC3T3E1 cells (Supplementary Figure S4B). The in vivo co-localization of these two proteins was observed in periostea of growing young mice, where the co-localization was more remarkable in matured osteoblasts (Supplementary Figures S4C and D, arrows indicate the direction of osteoblast differentiation). Among the direct transcriptional target genes of Wnt/β-catenin signaling, only the expression of the osteogenic gene (Fgf18) but not the oncogenic genes (c-Myc and Cyclin D1)16, 17 were increased by Wnt3a treatment of pre-osteoblasts (Figure 4c). The Wnt3a-induced increases in ALP and Fgf18 expression levels were suppressed by CXXC5 overexpression (Figure 4c). In addition, Wnt3a-induced β-catenin accumulation and Wnt/β-catenin signaling reporter gene activation were abolished by CXXC5 overexpression in MC3T3E1 cells (Figures 4d and e). Human embryonic kidney 293 (HEK293) cells, a normal cell line with high transfection efficiency, were introduced for further investigations of molecular mechanism. Similar but marginal effects of CXXC5 overexpression were observed in HEK293 cells (Supplementary Figures S5A and B). Previous observations in neuronal stem cells revealed that CXXC5 interacted with Dvl, a positive regulator suppressing the formation of the β-catenin complex, to inhibit the Wnt/β-catenin pathway.9 We found that CXXC5 interacted with Dvl in MC3T3E1 cells as well, but only when MC3T3E1 cells were treated with Wnt3a (Figure 4d). This Wnt3a-dependent Dvl–CXXC5 interaction was cell-type specific, as it was not observed in HEK293 cells (Supplementary Figure S5C).
CXXC5 possesses a Dvl-binding motif (DBM) at its C terminus, which is an essential motif for Idax to bind with the Dvl PDZ domain18 (Supplementary Figure S5D). Overexpression of CXXC5ΔDBM, which lacks the DBM, did not inhibit Wnt3a-induced activation of the Wnt/β-catenin pathway in either MC3T3E1 cells (Figures 4d and e) or HEK293 cells (Supplementary Figure S5E). As expected, CXXC5ΔDBM failed to bind Dvl in MC3T3E1 cells, even when the cells were treated with Wnt3a (Figure 4d). Furthermore, CXXC5ΔDBM did not affect the Wnt3a-induced increases in the transcriptional activity of the Wnt/β-catenin reporter gene (Figure 4e) or in ALP and Fgf18 mRNA levels (Figure 4f). In summary, CXXC5 is a negative-feedback regulator that is induced by Wnt/β-catenin signaling during osteoblast differentiation and functions via an osteoblast-specific interaction with Dvl in a Wnt3a-dependent manner.
Blockade of the Dvl–CXXC5 interaction by a competing peptide activates the Wnt/β-catenin pathway, and promotes osteoblast differentiation and ex vivo calvaria growth
To investigate whether disruption of the Dvl–CXXC5 interaction can activate Wnt/β-catenin signaling, a competitor peptide that can bind with Dvl was synthesized (Figure 5a). This peptide consists of a protein transduction domain (PTD; PolyR),19 linker, DBM and lysine conjugated to fluorescein isothiocyanate (Figure 5a). In MC3T3E1 cells, nuclear β-catenin levels and the transcriptional activity of the Wnt/β-catenin reporter gene were significantly increased following loading with PolyR-DBM (Figures 5b and c). ALP, BSP and Fgf18 mRNA levels were also increased after PolyR-DBM treatment (Figure 5d).
The role of CXXC5 as a negative-feedback regulator of the Wnt/β-catenin pathway in MC3T3E1 cells was further suggested by the significant synergistic increase in β-catenin protein levels and Wnt/β-catenin signaling reporter activity by treatment of Wnt3a recombinant protein (Wnt3a) with PolyR-DBM compared with treatment of Wnt3a or PolyR-DBM alone (Figures 5e and f). The co-treatment also critically enhanced both the level and the nuclear localization of β-catenin compared with Wnt3a or PolyR-DBM treatment alone (Figure 5g). These results confirm that CXXC5 is a negative-feedback regulator of Wnt/β-catenin signaling, and demonstrate that targeting the Dvl–CXXC5 interaction might be a feature of bone anabolic agents.
To show the effects of PolyR-DBM on bone formation, we used the ex vivo calvaria culture system, providing convenient way to access bone formation via the culture of a piece of bone tissue.20 Calvariae were cultured with PolyR-DBM and internalization of the peptide into calvariae was confirmed by fluorescence imaging (Figure 6a). β-Catenin accumulation in calvarial cells was observed in the PolyR-DBM-treated group, which showed activation of Wnt/β-catenin signaling in the cells, but not in the untreated group (Figure 6a). PolyR-DBM-treated calvariae exhibited a faster growth rate than calvariae of the non-treated group (Figures 6b and c). These results show that disruption of Dvl–CXXC5 interaction can promote bone formation of ex vivo-cultured tissues, as well as osteogenic differentiation of osteoblasts.
Discussion
Two negative regulators of the Wnt/β-catenin pathway have been identified as negative-feedback regulators of osteoblast differentiation and bone formation. Dkk-1, expressed in osteoblasts and osteocytes, prevents Wnt signaling by interacting with Wnt coreceptors.21 Sclerostin, expressed in osteocytes exclusively, inhibits osteoblastogenesis and bone formation in vivo by binding to Wnt coreceptors low-density lipoprotein receptor-related protein 5 and 6.22 These two extracellular antagonists of the Wnt/β-catenin pathway showed bone tissue-specific expression, and bone formation was accelerated following their genetic ablation or functional inhibition.5 Here we identified that CXXC5 is an osteoblast-specific interacellular negative-feedback regulator of the Wnt/β-catenin pathway and osteoblast differentiation. Although the expression of CXXC5 was observed in several tissues besides bone, the Wnt-dependent interaction of CXXC5 with Dvl was revealed as an osteoblast-specific event.
Our findings show that CXXC5 is transcriptionally induced by the strong activation of Wnt/β-catenin signaling at the late stage of osteoblast differentiation and has a role as a negative-feedback regulator through its direct interaction with Dvl (Figure 6d). The release of the negative-feedback regulation by PTD-DBM induced the expression of osteogenic genes promoting osteoblast differentiation. Furthermore, a significant synergic activation of the Wnt/β-catenin pathway by co-treatment with Wnt3a and PTD-DBM was revealed by an analysis of pre-osteoblasts. The synergistic effect confirms the role of CXXC5 as a negative-feedback regulator of the Wnt/β-catenin pathway in pre-osteoblasts.
In the absence of this negative-feedback regulator, the Wnt/β-catenin pathway was critically activated and subsequently increased DMP-1 levels in mouse osteocytes. DMP-1 is expressed primarily in osteocytes and promotes the mineralization of matrix and the maturation of osteoblasts into osteocytes.11 The increase in DMP-1 levels in femurs of CXXC5−/− mice indicates an increase in bone mineral deposition and an acceleration of osteoblast-to-osteocyte transition in the bone. Indeed, CXXC5−/− mice showed high bone mass phenotype, and bone formation rates were increased in these mice as revealed by histomorphometrical analyses. In addition, we observed increases in osteocyte network in the femurs of CXXC5−/− mice. The network of osteocytes is essential for the function of osteocytes as mechanosensors, which is required for bone maintenance, and an impaired osteocyte network is associated with the failure of bone to repair itself.23 These observations indicate that mouse bone quality is improved by CXXC5 knockout.
In conclusion, we characterized CXXC5 as a negative-feedback regulator of Wnt/β-catenin signaling in osteoblasts, and propose the Dvl–CXXC5 interaction as an essential mechanism for the negative-feedback regulation of osteoblast differentiation and bone formation.
Materials and Methods
Cell culture, transfections and reporter assays
MC3T3E1 and HEK293 cells were maintained in α-minimal essential medium (α-MEM, Invitrogen, Carlsbad, CA, USA) and Dulbecco's-modified Eagle's medium (Invitrogen), respectively, supplemented with 10% fetal bovine serum (Invitrogen) and 100 units/ml penicillin G streptomycin (Invitrogen). For osteoblast differentiation, MC3T3E1 cells were grown in α-MEM with either ascorbic acid (50 mg/l; Sigma, St. Louis, MO, USA) and β-glycerol-phosphate (10 mM; Sigma) or recombinant Wnt3a (100 ng/ml; R&D Systems, Minneapolis, MN, USA). MC3T3E1 cells were transfected with 0.5 μg of the vector pcDNA3.1, pcDNA3.1-CXXC5-Myc or pcDNA3.1-CXXC5ΔDBM-Myc. For the reporter assay, all cells were co-transfected with 0.5 μg of pTOPFLASH or pFOPFLASH and 50 ng of pCMV-β-gal. The relative luciferase activity is presented as the ratio of pTOPFLASH to pFOPFLASH and normalized to β-galactosidase activity. The PolyR-DBM peptides described in Figure 5a were synthesized by Peptide 2.0 Inc (Chantilly, VA, USA).
Bone mass measurements, skeletal analyses and bone preparation
The BMD of 11-week-old male mice was determined using a PIXImus II densitometer (GE Healthcare, Piscataway, NJ, USA). The bone phenotypes were measured in male mice to avoid variations resulting from female sex hormones. The mouse femurs were scanned using a CT system (Skyscan 1072, Skyscan, Aartselaar, Belgium). The scanned image data were reconstructed to create 3D images and analyzed using the CT-Analyzing Program (Skyscan). For femoral trabecular bone analysis, the femurs were scanned with a voxel size of 10 μm, beginning at the end of the growth plate and extending proximally along the diaphysis, and 80 continuous slices (beginning at 0.1 mm from the most proximal aspect of the growth plate in which both condyles were no longer visible) were selected for analysis. For skeleton staining, the skeletons were fixed in 95% ethanol and stained with Alizarin red S solution. The images were captured using a SMZ645 Nikon microscope (Nikon, Tokyo, Japan).
Mouse calvaria extraction and ex vivo culture
The parietal bones were isolated from the calvaria of 4-day-old mice as described previously.20 For ex vivo culture, each calvaria was placed on a stainless steel mesh bridge support containing α-MEM with 10% FBS (Invitrogen) and 100 units/ml penicillin G streptomycin (Invitrogen). The medium was exchanged every 2 days. The calvariae were maintained at 37 °C in a humidified atmosphere of 5% CO2.
IP and immunoblot analyses
The cells were lysed in RIPA buffer (50 mM Tris chloride (pH 8.0), 120 mM sodium chloride, 0.5% (v/v) nonidet P-40, 5 μg/ml leupeptin, 10 μg/ml aprotinin, 50 μg/ml PMSF, 0.2 mM sodium orthovanadate and 100 mM sodium fluoride) for immunoblot analyses. IP was performed as described previously.10 To monitor the interactions between overexpressed proteins, 400 μg of lysates of transfected cells were subjected to IP with 2 μg of anti-Dvl-1 (3F12; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Myc (9B11; Cell Signaling Technology, Beverly, MA, USA) or anti-CXXC5 antibody. Immunoblot analyses were performed using anti-β-catenin (E-5; Santa Cruz Biotechnology; 1 : 3000), anti-Dvl-1 (1 : 1000), anti-Myc (Cell Signaling Technology; 1 : 5000) or anti-α-tubulin (Calbiochem, San Diego, CA, USA; 1 : 5000) followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotechnology) and visualization using enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA).
Conventional PCR and reverse transcriptase PCR
The cDNA preparation and reverse transcriptase PCR (RT-PCR) analyses were performed as described previously.14 Briefly, RT-PCR was performed with total RNA (1 μg), and reverse transcription was performed with the following primers: BSP, forward 5′-AATGGAGACGGCGATAGTTC-3′ and reverse 5′-GTCCTCATAAGCTCGGTAAG-3′ ALP, forward 5′-GGGACTGGTACTCGGATAACGA-3′ and reverse 5′-CTGATATGCGATGTCCTTGCA-3′ Fgf18, forward 5′-ACTGCTGTGCTTCCAGGTTC-3′ and reverse 5′-CCCAGGACTTGAATGTGCTT-3′ CXXC5, forward 5'-CAGTAGCAGCAGCAGTAACA-3′ and reverse 5′-CACTCATCAGTGGCAGGTGT-3′ and hypoxanthine guanine phospho-ribosyltransferase (HPRT), forward 5′-CCTGCTGGATTACATTAAAGCACT-3′ and reverse GTCAGGGCATTCCAACAACAAA-3′. G-Taq DNA polymerase (COSMO Genetech, Seoul, Korea) was used for all PCRs, including cloning, genotyping and RT-PCR.
Histochemical analysis
The femurs of 11-week-old mice and the calvariae of 4-day-old mice were fixed in 4% paraformaldehyde in phosphate-buffered saline. The bones were then decalcified in 10 mM EDTA and embedded in paraffin. Five-micrometer tissue sections were deparaffinized in 100% xylene followed by re-hydration with sequential 100–50% ethanol washes. The sections were stained with H&E or Safranin O solution. For immunohistochemical analyses, antigen retrieval was performed by incubation in a citrate buffer at 60 °C for 1 h or in a buffer containing proteinase K at 37 °C for 20 min. To stain with 3,3′-diaminobenzidine (DAB), the sections were treated with H2O2 to inactivate endogenous tissue peroxidases. The following primary antibodies were used: anti-CXXC5 (1 : 20), anti-β-catenin (1 : 100) and anti-DMP-1 (1 : 100; Sigma). For immunofluorescence staining and analysis, the sections were incubated with Alexa Fluor 488- or Alexa Fluor 555-conjugated IgG secondary antibody (Molecular Probes, Eugene, OR, USA; 1 : 200), counterstained with 4′,6-diamidino-2-phenylindole (Boehringer Mannheim, Mannheim, Germany) and mounted in Gel/Mount media (Dako, Glostrup, Denmark). An LSM510META confocal microscope (Carl Zeiss, Jena, Germany) was used to capture the fluorescent micrographs of the stained sections. For DAB staining, the sections were incubated with HRP-conjugated IgG secondary antibody (Dako; 1 : 200), followed by DAB substrate reagent (Dako). The sections were counterstained with Mayer's hematoxylin (Junsei Chemical, Tokyo, Japan), and light micrographs were captured using a SMZ645 Nikon microscope (Nikon). To minimize variation in the measurement of calvaria thickness, sagittal sections obtained from near a specific position (500 μm far from midline suture of calvaria) were selected, and the region of interest (ROI) was set on parietal bone nearby the coronal suture. The thicknesses of the bone in the ROI were measured using Image Pro software (Media Cybernetics Inc., Silver Spring, MD, USA).
Statistical analysis
Statistically significant differences were calculated using Student's t-test and Kruskal–Wallis test. P-values <0.05 were considered significant (*P<0.05, **P<0.01 and ***P<0.001). For all statistical analyses, Statistical Package for the Social Sciences (SPSS 21, IBM, Chicago, IL, USA) statistical program was used.
Acknowledgments
We thank Sean Bong Lee and Ho Jin Lee for their helpful discussion and comments on the manuscript. This work was funded by the Ministry of Future Creation and Science (MFCS) of Korea; Translational Research Center for Protein Function Control (2009-0083522), Mid-career Researcher Program (2012-010285) and Stem Cell Research Project (2010-0020235). This work was also supported by the Ministry of Knowledge Economy (through the Korea Research Institute of Chemical Technology (SI-0905, SI-1005, SI-1105, SI-1205 and SI-1304)). H-YK, J-YY, S-HL and K-WC were supported by a BK21 studentship from the NRF and the MFCS.
Glossary
- α-MEM
α-minimal essential medium
- ALP
alkaline phosphatase
- BMD
bone mineral density
- BSP
bone sialoprotein
- CT
computed tomography
- DAB
3,3′-diaminobenzidine
- DBM
Dvl-binding motif
- DMP-1
dentin matrix acidic phosphoprotein-1
- Dvl
Dishevelled
- Fgf18
fibroblast growth factor 18
- H&E
hematoxylin and eosin
- PTD
protein transduction domain
The authors declare no conflict of interest.
Footnotes
Supplementary Information accompanies this paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Edited by H-U Simon
Supplementary Material
References
- Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010;11:219–227. doi: 10.1007/s11154-010-9153-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 2012;13:27–38. doi: 10.1038/nrm3254. [DOI] [PubMed] [Google Scholar]
- Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276–1287. doi: 10.1016/S0140-6736(10)62349-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Regard JB, Zhong Z, Williams BO, Yang Y. Wnt signaling in bone development and disease: making stronger bone with Wnts. Cold Spring Harb Perspect Biol. 2012;4:1–17. doi: 10.1101/cshperspect.a007997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009;13:485–496. doi: 10.1517/14728220902841961. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ravasi T, Huber T, Zavolan M, Forrest A, Gaasterland T, Grimmond S, et al. Systematic characterization of the zinc-finger-containing proteins in the mouse transcriptome. Genome Res. 2003;13:1430–1442. doi: 10.1101/gr.949803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pendino F, Nguyen E, Jonassen I, Dysvik B, Azouz A, Lanotte M, et al. Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. Blood. 2009;113:3172–3181. doi: 10.1182/blood-2008-07-170035. [DOI] [PubMed] [Google Scholar]
- Kim HY, Yang DH, Shin SW, Kim MY, Yoon JH, Kim S, et al. CXXC5 is a transcriptional activator of Flk-1 and mediates bone morphogenic protein-induced endothelial cell differentiation and vessel formation. FASEB J. 2014;28:615–626. doi: 10.1096/fj.13-236216. [DOI] [PubMed] [Google Scholar]
- Andersson T, Södersten E, Duckworth JK, Cascante A, Fritz N, Sacchetti P, et al. CXXC5 is a novel BMP4-regulated modulator of Wnt signaling in neural stem cells. J Biol Chem. 2009;284:3672–3681. doi: 10.1074/jbc.M808119200. [DOI] [PubMed] [Google Scholar]
- Hino S, Kishida S, Michiue T, Fukui A, Sakamoto I, Takada S, et al. Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol Cell Biol. 2001;21:330–342. doi: 10.1128/MCB.21.1.330-342.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qin C, D'Souza R, Feng JQ. Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis. J Dent Res. 2007;86:1134–1141. doi: 10.1177/154405910708601202. [DOI] [PubMed] [Google Scholar]
- Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. 2008;42:606–615. doi: 10.1016/j.bone.2007.12.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stuart AJ, Smith DA. Use of the fluorochromes xylenol orange, calcein green, and tetracycline to document bone deposition and remodeling in healing fractures in chickens. Avian Dis. 1992;36:447–449. [PubMed] [Google Scholar]
- Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT, et al. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res. 1999;14:893–903. doi: 10.1359/jbmr.1999.14.6.893. [DOI] [PubMed] [Google Scholar]
- Reinhold MI, Naski MC. Direct interactions of Runx2 and canonical Wnt signaling induce FGF18. J Biol Chem. 2007;282:3653–3663. doi: 10.1074/jbc.M608995200. [DOI] [PubMed] [Google Scholar]
- He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509–1512. doi: 10.1126/science.281.5382.1509. [DOI] [PubMed] [Google Scholar]
- Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999;96:5522–5527. doi: 10.1073/pnas.96.10.5522. [DOI] [PMC free article] [PubMed] [Google Scholar]
- London TB, Lee HJ, Shao Y, Zheng J. Interaction between the internal motif KTXXXI of Idax and mDvl PDZ domain. Biochem Biophys Res Commun. 2004;322:326–332. doi: 10.1016/j.bbrc.2004.07.113. [DOI] [PubMed] [Google Scholar]
- Matsushita M, Matsui H. Protein transduction technology. J Mol Med. 2005;83:324–328. doi: 10.1007/s00109-004-0633-1. [DOI] [PubMed] [Google Scholar]
- Reynolds JJ, Minkin C, Morgan DB, Spycher D, Fleisch H. The effect of two diphosphonates on the resorption of mouse calvaria in vitro. Calcif Tissue Res. 1972;10:302–313. doi: 10.1007/BF02012561. [DOI] [PubMed] [Google Scholar]
- Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357:905–916. doi: 10.1056/NEJMra067395. [DOI] [PubMed] [Google Scholar]
- Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280:19883–19887. doi: 10.1074/jbc.M413274200. [DOI] [PubMed] [Google Scholar]
- Vashishth D, Verborgt O, Divine G, Schaffler MB, Fyhrie DP. Decline in osteocyte lacunar density in human cortical bone is associated with accumulation of microcracks with age. Bone. 2000;26:375–380. doi: 10.1016/S8756-3282(00)00236-2. [DOI] [PubMed] [Google Scholar]
- Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595–610. doi: 10.1002/jbmr.5650020617. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.